Natalizumab (Tysabri®)

Assessment Status Full HTA Assessment
Drug Natalizumab
Brand Tysabri®
Indication For the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.
Assessment Process
NCPE assessment re-commenced 23/01/2007
NCPE assessment completed 03/04/2007
NCPE assessment outcome Reimbursement recommended.

Natalizumab could be considered borderline cost effective in the Irish healthcare setting. In view of the uncertainty surrounding some of the ICERs a follow up review is advised. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.

Technical Summary